- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.02. | Aelis Farma Announces Its 2025 Financial Calendar | 169 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 18.11.24 | Aelis Farma Announces the Positive Results of Its Clinical Phase 1/2 Study with AEF0217 in Young Adults With Down Syndrome | 290 | Business Wire | The CB1-SSi AEF0217 successfully met the safety (primary), pharmacokinetic (secondary) and efficacy (secondary and exploratory) objectives of this phase 1/2 performed in young adults with Down... ► Artikel lesen | |
| 26.09.24 | Aelis Farma: Availability of the 2024 Half-year Financial Report | 245 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announces that its half-year... ► Artikel lesen | |
| 25.09.24 | Aelis Farma Announces Half-year Financial Results for 2024 and Provides Corporate and Development Update | 334 | Business Wire | A solid cash position of €12.6 million at June 30, 2024, not including the gross amount of €4.5 million share offering which occurred at the end of July and other non-dilutive financing currently... ► Artikel lesen | |
| AELIS FARMA Aktie jetzt für 0€ handeln | |||||
| 04.09.24 | Indivior reports "disappointing" results for study with Aelis Farma | 8 | Alliance News | ||
| 04.09.24 | Indivior PLC: Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder | 412 | PR Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN... ► Artikel lesen | |
| 04.09.24 | Aelis Farma Announces the Results of Its Clinical Phase 2B Study with AEF0117, Among Participants with Cannabis Use Disorder (CUD) | 369 | Business Wire | The main objective of this phase 2B study was to demonstrate that AEF0117 reduces cannabis use and to determine the endpoints as well as the optimal dosage of AEF0117 for use in future studies.... ► Artikel lesen | |
| 31.07.24 | Aelis Farma Announces the Successful Completion of Its Reserved Offering for a Total Gross Amount of €4.5 Million | 432 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS the "Company"), a... ► Artikel lesen | |
| 30.07.24 | Aelis Farma: Launch of a Reserved Offering of Approximately €5 Million | 479 | Business Wire | NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN Launch of a Reserved Offering of new shares for c. €5 million aimed at categories... ► Artikel lesen | |
| 24.06.24 | Aelis Farma: Availability of the Description of the Share Buyback Program | 273 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS) (Paris:AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces... ► Artikel lesen | |
| 04.06.24 | Results of Aelis Farma Combined General Meeting of June 4, 2024 | 363 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases announces that all... ► Artikel lesen | |
| 14.05.24 | Aelis Farma: Combined General Meeting of June 4, 2024: Availability of Preparatory Documents and Participation and Voting Procedures | 434 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, informs its shareholders... ► Artikel lesen | |
| 25.04.24 | Aelis Farma: Availability of the 2023 Universal Registration Document | 312 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces the publication... ► Artikel lesen | |
| 18.04.24 | Aelis Farma Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder | 347 | Business Wire | The last patient in the clinical phase 2b trial with AEF0117 for the treatment of cannabis use disorder has completed its last medical visit, paving the way for the release of study results in... ► Artikel lesen | |
| 02.04.24 | Aelis Farma Reports Its 2023 Annual Financial Results and Confirms Its 2024 Outlook | 433 | Business Wire | 2023 has been marked by key milestones for the Company's two drug candidates: AEF0117: completion of patient recruitment for the phase 2b study with 333 patients in excessive cannabis... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 63,20 | +6,99 % | Tempus AI Aktie: Langfristige Planung vorgestellt | Der Technologiekonzern Tempus AI verzeichnet derzeit bemerkenswerte Bewegungen im Aktienhandel, wobei mehrere hochrangige Führungskräfte in der vergangenen Woche umfangreiche Aktienverkäufe tätigten.... ► Artikel lesen | |
| EVOTEC | 8,250 | -0,42 % | Evotec Aktie: Steht das Schlimmste noch bevor? | Die Evotec-Aktie verzeichnete am Mittwoch einen spürbaren Rückschlag an der Börse. Im XETRA-Handel musste das Biotechnologieunternehmen einen Kursverlust von 4,2 Prozent hinnehmen, wodurch der Aktienkurs... ► Artikel lesen | |
| QIAGEN | 37,695 | +0,05 % | ANALYSE-FLASH: Berenberg senkt Ziel für Qiagen auf 48 Euro - 'Buy' | HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 54,90 auf 48,00 Euro gesenkt und die Einstufung auf "Buy" belassen. Das vierte Quartal sei solide gewesen, auch wenn... ► Artikel lesen | |
| BIONTECH | 109,00 | +3,12 % | BioNTech-Aktie: Geht's jetzt wieder hoch? | Es ist still geworden um die BioNTech-Aktie. Sie kommt seit drei Monaten nicht vom Fleck und notiert aktuell bei 119,58 US$. Ist das die Ruhe vor dem nächsten Sturm? Übernahme abgeschlossen Die letzte... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 2,460 | +101,64 % | Pre-market Movers: Enveric Biosciences, Interactive Strength, Flywire, Grocery Outlet Holding, National Vision Holdings | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.50 A.M. ET).In the Green Enveric Biosciences, Inc. (ENVB) is up over 155%... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,260 | +1,54 % | Spotlight on Recursion Pharmaceuticals: Analyzing the Surge in Options Activity | ||
| ONCO-INNOVATIONS | 1,770 | -4,84 % | EQS-Media: Onco-Innovations Ltd.: Vielversprechender Wachstumsimpuls? Onco-Tochter Inka Health meldet provisorische USPTO-Patentanmeldung für SynoGraph | EQS-Media / 22.02.2025 / 13:05 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass seine hundertprozentige Tochtergesellschaft... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 42,350 | +2,48 % | Tarsus stock holds Buy rating and $73 target at H.C. Wainwright | ||
| DAY ONE BIOPHARMACEUTICALS | 9,945 | -15,86 % | Day One Biopharmaceuticals stock target cut to $36 at H.C. Wainwright | ||
| MODERNA | 32,165 | -1,33 % | Moderna-Aktie mit Kursverlusten (32,8655 €) | Im US-amerikanischen Wertpapierhandel liegt die Moderna-Aktie derzeit im Minus. Zuletzt zahlten Investoren für das Papier 34,40 US-Dollar. Jahreschart der Moderna Inc-Aktie, Stand 20.02.2025 Am US-amerikanischen... ► Artikel lesen | |
| AMGEN | 292,25 | -2,65 % | Aktien New York: Indizes zunehmend unter Druck am Ende einer schwachen Woche | NEW YORK (dpa-AFX) - An den New Yorker Börsen hat sich am Freitag die Kursschwäche verfestigt. Der Leitindex Dow Jones Industrial sank zuletzt um 1,60 Prozent auf 43.469 Punkte. Der von Technologieaktien... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,830 | -6,74 % | Beam Therapeutics Inc. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Beam Therapeutics Inc. (BEAM):Earnings: -$90.35 million in Q4 vs. $142.80 million in the same period last year.
EPS: -$1.09 in... ► Artikel lesen | |
| ARCELLX | 61,64 | -1,72 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| STRYKER | 374,40 | +0,89 % | Stryker Corporation: Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment | Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 54,59 | +1,11 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen |
Das Unternehmen AELIS FARMA SAS kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,020 (-1,19 %) liegt der Kurs bei 1,660 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AELIS FARMA SAS finden Sie auf Wallstreet Online.
